Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 5 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Solid Tumors Market in Asia Pacific to 2019 - Introduction | 11 | 1 |
| Introduction | 11 | 1 |
| Solid Tumors Market in Asia Pacific to 2019 - Therapeutic Landscape | 12 | 33 |
| Bladder Cancer | 12 | 1 |
| Symptoms | 12 | 1 |
| Etiology | 12 | 1 |
| Pathophysiology | 12 | 1 |
| Diagnosis | 12 | 1 |
| Physical Examination | 12 | 1 |
| Urological Tests | 13 | 1 |
| Cystoscopy and Transurethral Resection of Bladder Tumor | 13 | 1 |
| Imaging Tests | 13 | 1 |
| Classification | 13 | 1 |
| Epidemiology | 14 | 1 |
| Prognosis and Disease Staging | 15 | 1 |
| Staging | 15 | 2 |
| Treatment Options | 17 | 1 |
| Non-Pharmacological Care | 17 | 1 |
| Pharmacological | 18 | 1 |
| Treatment Algorithms and Prescribing Habits | 19 | 3 |
| Ovarian Cancer | 22 | 1 |
| Symptoms | 22 | 1 |
| Etiology | 22 | 1 |
| Pathophysiology | 23 | 1 |
| Diagnosis | 23 | 1 |
| Physical Examination | 23 | 1 |
| Blood Tests | 23 | 1 |
| Human Chorionic Gonadotropin Test | 24 | 1 |
| Ultrasound and CT Scans | 24 | 1 |
| Biopsy | 24 | 1 |
| Classification | 25 | 1 |
| Epidemiology | 25 | 1 |
| Prognosis and Disease Staging | 26 | 1 |
| Staging | 27 | 1 |
| Treatment Options | 28 | 1 |
| Surgery | 28 | 1 |
| Radiation Therapy | 28 | 1 |
| Chemotherapy | 29 | 1 |
| Treatment Algorithm | 29 | 2 |
| Pancreatic Cancer | 31 | 1 |
| Symptoms | 31 | 1 |
| Etiology | 31 | 1 |
| Pathophysiology | 32 | 1 |
| Disease Initiation | 32 | 1 |
| Disease Progression | 32 | 1 |
| Diagnosis | 32 | 1 |
| Physical Examination | 32 | 1 |
| Blood Tests | 32 | 1 |
| Classification | 32 | 1 |
| Epidemiology | 32 | 2 |
| Prognosis and Disease Staging | 34 | 1 |
| Prognosis | 34 | 1 |
| Survival Rates | 34 | 1 |
| Staging | 34 | 2 |
| Treatment Algorithm | 36 | 1 |
| Prostate Cancer | 37 | 1 |
| Symptoms | 37 | 1 |
| Etiology | 37 | 1 |
| Pathophysiology | 37 | 1 |
| Disease Initiation | 37 | 1 |
| Disease Progression | 37 | 1 |
| Co-Morbidities and Complications | 38 | 1 |
| Diagnosis | 38 | 1 |
| Classification | 39 | 1 |
| Localized or Locally Advanced Prostate Cancer | 39 | 1 |
| Metastatic Prostate Cancer | 39 | 1 |
| Epidemiology | 39 | 2 |
| Prognosis and Disease Staging | 41 | 1 |
| Tumor, Nodes, Metastasis Staging System | 41 | 1 |
| Jewett-Whitmore system | 42 | 1 |
| Treatment Options | 43 | 1 |
| Non-Pharmacological Treatment Options | 43 | 1 |
| Pharmacological Treatment | 43 | 1 |
| Treatment Algorithm | 44 | 1 |
| Solid Tumors Market in Asia Pacific to 2019 - Marketed Products | 45 | 12 |
| Bladder Cancer | 45 | 1 |
| Ovarian Cancer | 45 | 1 |
| Pancreatic Cancer | 46 | 1 |
| Prostate Cancer | 47 | 1 |
| Key Marketed Products | 47 | 1 |
| Carboplatin | 47 | 1 |
| Cisplatin | 48 | 1 |
| Gemcitabine | 48 | 1 |
| Paclitaxel | 49 | 1 |
| Doxorubicin | 49 | 1 |
| Avastin (bevacizumab) | 50 | 1 |
| Tarceva (erlotinib) | 51 | 1 |
| Sutent (sunitinib) | 52 | 1 |
| Afinitor (everolimus) | 53 | 1 |
| Taxotere (docetaxel) | 54 | 1 |
| Zytiga (abiraterone acetate) | 54 | 2 |
| Jevtana (cabazitaxel) | 56 | 1 |
| Solid Tumors Market in Asia Pacific to 2019 - Pipeline Analysis | 57 | 16 |
| Bladder Cancer Pipeline | 57 | 1 |
| Overall Pipeline | 57 | 1 |
| Pipeline Analysis by Molecule Type | 58 | 1 |
| Pipeline Analysis by Mechanism of Action | 59 | 1 |
| Ovarian Cancer Pipeline | 60 | 1 |
| Overall Pipeline | 60 | 2 |
| Pipeline Analysis by Molecule Type | 62 | 1 |
| Pipeline Analysis by Mechanism of Action | 63 | 1 |
| Pancreatic Cancer Pipeline | 64 | 1 |
| Overall Pipeline | 64 | 1 |
| Pipeline Analysis by Molecule Type | 65 | 1 |
| Pipeline Analysis by Mechanism of Action | 66 | 1 |
| Prostate Cancer Pipeline | 67 | 1 |
| Overall Pipeline | 67 | 1 |
| Pipeline Analysis by Molecule Type | 68 | 1 |
| Pipeline Analysis by Mechanism of Action | 69 | 1 |
| Promising Drug Candidates in the Pipeline | 70 | 1 |
| Abraxane (albumin-bound paclitaxel) | 70 | 1 |
| AMG 386 (trebananib) | 70 | 1 |
| Votrient (pazopanib) | 71 | 1 |
| Xtandi (enzalutamide) | 72 | 1 |
| Solid Tumors Market in Asia Pacific to 2019- Market Forecast | 73 | 13 |
| Asia-Pacific Market | 73 | 1 |
| Treatment Usage Patterns | 73 | 1 |
| Annual Cost of Treatment | 73 | 1 |
| Market Size | 73 | 2 |
| India | 75 | 1 |
| Treatment Usage Patterns | 75 | 1 |
| Annual Cost of Treatment | 75 | 1 |
| Market Size | 75 | 2 |
| Australia | 77 | 1 |
| Treatment Usage Patterns | 77 | 1 |
| Annual Cost of Treatment | 77 | 1 |
| Market Size | 78 | 2 |
| China | 80 | 1 |
| Treatment Usage Patterns | 80 | 1 |
| Annual Cost of Treatment | 80 | 1 |
| Market Size | 80 | 2 |
| Japan | 82 | 1 |
| Treatment Usage Patterns | 82 | 1 |
| Annual Cost of Treatment | 82 | 1 |
| Market Size | 82 | 2 |
| Drivers and Barriers for the Solid Tumors Market in APAC | 84 | 1 |
| Drivers | 84 | 1 |
| Approvals of Targeted Therapy Options Are Expected To Drive Growth in Ovarian Cancer Segment Although Uptake Is Expected To Be Slower In India and China | 84 | 1 |
| Improved Drug Approval Timelines in Japan Could Contribute To Increased Access and Boost the Growth | 84 | 1 |
| Expanded healthcare insurance coverage in China is expected to increase access in oncology and boost growth | 84 | 1 |
| Barriers | 84 | 1 |
| Pricing Regulations in India and China Could Restrict Growth Prospects | 84 | 1 |
| Recent Drug Patent Litigations Attract Negative Image for the Region as an Investment Destination | 84 | 1 |
| Low Penetration and Low Access Still Plague the Asian Markets for Oncology Drugs | 85 | 1 |
| Solid Tumors Market in Asia Pacific to 2019 - Deals and Strategic Consolidations | 86 | 7 |
| Deals Analysis | 86 | 1 |
| Major Co-Development Deals | 87 | 1 |
| ScinoPharm Taiwan and Coland Enter into Agreement to Develop Generic Oncological Drugs | 88 | 1 |
| Bind Biosciences Enters into Agreement with Amgen to Develop Cancer Drugs | 88 | 1 |
| Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug | 88 | 1 |
| Merck Serono Enters into Co-Development Agreement with Threshold Pharma for TH-302, Pancreatic Cancer Drug | 89 | 1 |
| Seattle Genetics Exercises Option for Co-Development Agreement with Agensys (affiliate of Astellas) for ASG-15ME | 89 | 1 |
| Major Licensing Deals | 90 | 1 |
| Spectrum Pharma Amends Licensing Agreement with Allergan for Apaziquone | 91 | 1 |
| Chugai Pharma Enters Into Licensing Agreement with Debiopharm Group for FF284 | 91 | 1 |
| Baxter International Enters into Licensing Agreement with Onconova Therapeutics for Rigosertib | 91 | 1 |
| Dyax Enters Into Licensing Agreement with Kadmon for Oncology Drug | 91 | 1 |
| Medigene Extends Licensing Agreement with Syncore for EndoTAG-1 | 92 | 1 |
| Solid Tumors Market in Asia Pacific to 2019 - Appendix | 93 | 19 |
| Pipeline Drugs by Phase | 93 | 2 |
| Phase III | 93 | 1 |
| Pre-registration/NDA-filed | 94 | 1 |
| Market Forecasts to 2018 | 95 | 8 |
| APAC | 95 | 1 |
| Ovarian Cancer | 95 | 1 |
| Bladder Cancer | 95 | 1 |
| Pancreatic Cancer | 95 | 1 |
| Prostate Cancer | 96 | 1 |
| Australia | 96 | 1 |
| Ovarian Cancer | 96 | 1 |
| Bladder Cancer | 96 | 1 |
| Pancreatic Cancer | 97 | 1 |
| Prostate Cancer | 97 | 1 |
| China | 98 | 1 |
| Ovarian Cancer | 98 | 1 |
| Bladder Cancer | 98 | 1 |
| Pancreatic Cancer | 99 | 1 |
| Prostate Cancer | 99 | 1 |
| India | 99 | 1 |
| Ovarian Cancer | 99 | 1 |
| Bladder Cancer | 100 | 1 |
| Pancreatic Cancer | 100 | 1 |
| Prostate Cancer | 100 | 1 |
| Japan | 101 | 1 |
| Ovarian Cancer | 101 | 1 |
| Bladder Cancer | 101 | 1 |
| Pancreatic Cancer | 101 | 1 |
| Prostate Cancer | 102 | 1 |
| Market Definitions | 102 | 1 |
| Abbreviations | 102 | 2 |
| Sources | 104 | 3 |
| Research Methodology | 107 | 5 |
| Coverage | 107 | 1 |
| Secondary Research | 107 | 1 |
| Primary Research | 108 | 1 |
| Therapeutic Landscape | 108 | 1 |
| Epidemiology-Based Forecasting | 108 | 2 |
| Market Size by Geography | 110 | 1 |
| Geographical Landscape | 110 | 1 |
| Pipeline Analysis | 111 | 1 |
| Expert Panel Validation | 111 | 1 |
| Contact Us | 111 | 1 |
| Disclaimer | 111 | 1 |
